Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 70Lymphoma 54Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Hodgkin Disease 26Sarcoma 25Lymphoma, Follicular 25Lymphoma, Non-Hodgkin 24Leukemia 19Burkitt Lymphoma 17Multiple Myeloma 16Endometrial Neoplasms 15Neuroblastoma 14Ovarian Neoplasms 12Carcinoma, Hepatocellular 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Mantle-Cell 10Liposarcoma 9Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Leiomyosarcoma 8Histiocytoma, Malignant Fibrous 8Urinary Bladder Neoplasms 7Lymphoma, B-Cell, Marginal Zone 7Hemangiosarcoma 7Fibrosarcoma 7Wilms Tumor 6Triple Negative Breast Neoplasms 6Sarcoma, Synovial 6Neurofibrosarcoma 6

Interventions

Specimen Handling 2ribociclib 1exemestane 1durvalumab 1Taxes 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Drug Therapy 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anatomic Stage II Breast Cancer AJCC v8 × Doxorubicin × Clear all
NCT06058377 2026-06-03

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡